These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 28939921)

  • 1. Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.
    Khouzam N; Wesseling-Perry K
    Pediatr Nephrol; 2019 Jan; 34(1):1-10. PubMed ID: 28939921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease.
    Hénaut L; Chillon JM; Kamel S; Massy ZA
    Semin Nephrol; 2018 May; 38(3):233-250. PubMed ID: 29753400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
    Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
    Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
    Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineral metabolism and cardiovascular disease in CKD.
    Fujii H; Joki N
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications.
    Bover J; Ureña-Torres P; Górriz JL; Lloret MJ; da Silva I; Ruiz-García C; Chang P; Rodríguez M; Ballarín J
    Nefrologia; 2016; 36(6):597-608. PubMed ID: 27595517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
    Iwashita Y; Iwashita Y; Ito T; Shigematsu T
    Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineral bone disorders in chronic kidney disease.
    Hou YC; Lu CL; Lu KC
    Nephrology (Carlton); 2018 Oct; 23 Suppl 4():88-94. PubMed ID: 30298663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Vitamin D in Uremic Vascular Calcification.
    Hou YC; Liu WC; Zheng CM; Zheng JQ; Yen TH; Lu KC
    Biomed Res Int; 2017; 2017():2803579. PubMed ID: 28286758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review.
    Latif F; Khalid MM; Khan F; Omar Z; Ali FA
    J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):410-5. PubMed ID: 23392553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and management of vascular calcification in CKD and dialysis patients.
    Kakani E; Elyamny M; Ayach T; El-Husseini A
    Semin Dial; 2019 Nov; 32(6):553-561. PubMed ID: 31464003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications.
    Salanova Villanueva L; Sánchez González C; Sánchez Tomero JA; Aguilera A; Ortega Junco E
    Nefrologia; 2016; 36(4):368-75. PubMed ID: 27118192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bone in CKD-mediated mineral and vascular disease.
    Khouzam NM; Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2015 Sep; 30(9):1379-88. PubMed ID: 25168424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D and Calcimimetics in Cardiovascular Disease.
    Lim K; Hamano T; Thadhani R
    Semin Nephrol; 2018 May; 38(3):251-266. PubMed ID: 29753401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches.
    Düsing P; Zietzer A; Goody PR; Hosen MR; Kurts C; Nickenig G; Jansen F
    J Mol Med (Berl); 2021 Mar; 99(3):335-348. PubMed ID: 33481059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.
    Kaur R; Singh R
    Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.